MedTrace Logo

The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin

NCT02106767 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-01-23

No results posted yet for this study

Summary

The effect of transporter inhibition by rifampin on the pharmacokinetics of rosuvastatin will be studied in clinical trial in White and Asian healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

Rosuvastatin

Rosuvastatin 20mg po x1

DRUG

Rosuvastatin plus rifampin

Rifampin 600mg IV infused over 30 minutes followed by rosuvastatin 20mg PO x1

Sponsors & Collaborators

Principal Investigators

  • Leslie Z Benet, PhD · University of California, San Francisco

  • Lynda Frassetto, M.D. · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-08-07
Completion
2016-08-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02106767 on ClinicalTrials.gov